GlassScriptPhysician profile
Venkata Vosuri
NPI 1861603201
$6,313.75
in general payments reported to CMS, 2019-2025
54 companies · $2,227 in 2025
The $2,227 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2021: $546 · 2022: $864 · 2023: $571 · 2024: $1,943 · 2025: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,945 · Consulting Fee: $725 · Education: $71.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.69 |
| Consulting Fee | $725.00 |
| Education | $71.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $808.70 | 2023-2025 | Imfinzi, Enhertu, Lynparza |
| Pfizer INC. | $430.97 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $342.80 | 2024-2025 | |
| Sobi, INC | $301.87 | 2024-2025 | |
| Abbvie INC. | $256.38 | 2024-2025 | |
| Incyte Corporation | $243.21 | 2021-2025 | Jakafi |
| Eisai INC. | $224.33 | 2019-2024 | |
| Genzyme Corporation | $203.63 | 2022-2025 | |
| Novocure INC. | $194.74 | 2021 | |
| Astellas Pharma US INC | $191.21 | 2022-2025 | Xtandi, Vyloy |
| Merck Sharp & Dohme LLC | $178.97 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Array Biopharma INC | $176.95 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Epizyme, INC. | $174.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.67 | 2023-2025 | Livtencity, Ninlaro, Fruzaqla |
| Daiichi Sankyo INC. | $147.87 | 2024-2025 | Enhertu, Datroway |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $145.41 | 2024-2025 | Trodelvy |
| Blueprint Medicines Corporation | $132.29 | 2022 | |
| Paratek Pharmaceuticals, INC. | $124.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $122.24 | 2023-2025 | Libtayo, Lynozyfic |
| Adc Therapeutics America, INC. | $117.75 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $111.64 | 2025 | Monoferric |
| Puma Biotechnology, INC. | $107.32 | 2022-2025 | |
| Celgene Corporation | $105.58 | 2024-2025 | Reblozyl |
| Janssen Scientific Affairs, LLC | $102.31 | 2022 | |
| Genmab U.S., INC. | $90.53 | 2023-2024 | Epkinly |
| Foundation Medicine, INC. | $84.26 | 2022 | |
| Genentech USA, INC. | $82.72 | 2024-2025 | Polivy, Venclexta, Tecentriq Hybreza |
| Glaxosmithkline, LLC. | $77.25 | 2024-2025 | Zejula, Jemperli |
| Janssen Biotech, INC. | $72.77 | 2022-2025 | Rybrevant, Erleada |
| Alexion Pharmaceuticals, INC. | $71.74 | 2024-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $67.95 | 2024-2025 | Opdivo |
| Alnylam Pharmaceuticals INC. | $64.59 | 2022 | |
| Dendreon Pharmaceuticals LLC | $54.94 | 2024-2025 | Provenge |
| Sumitomo Pharma America, INC. | $45.82 | 2025 | Orgovyx |
| Beigene USA, INC. | $42.05 | 2023-2025 | Brukinsa, Tevimbra |
| Myriad Genetic Laboratories, INC. | $39.42 | 2025 | Myrisk |
| Beone Medicines USA, INC. | $35.24 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $35.08 | 2024-2025 | Pyrukynd |
| Corcept Therapeutics | $32.87 | 2025 | Korlym |
| Immunocore Limited | $30.04 | 2025 | Kimmtrak |
| Syndax Pharmaceuticals, INC. | $27.06 | 2025 | Revuforj |
| Bayer Healthcare Pharmaceuticals INC. | $26.05 | 2025 | |
| Springworks Therapeutics, INC. | $24.05 | 2025 | Ogsiveo |
| Lilly USA, LLC | $22.76 | 2023 | Jaypirca |
| Tempus Ai, INC | $20.17 | 2025 | Xt Cdx |
| Amgen INC. | $19.51 | 2023 | Nplate, Vectibix, Xgeva |
| Deciphera Pharmaceuticals INC. | $19.18 | 2025 | Qinlock, Romvimza |
| Stemline Therapeutics INC. | $18.44 | 2025 | Orserdu |
| Servier Pharmaceuticals LLC | $17.86 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.73 | 2025 | |
| Kyowa Kirin, INC. | $16.98 | 2025 | |
| Seagen INC. | $16.60 | 2023 | Tukysa |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Pharmaessentia USA Corporation | $14.39 | 2025 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkata Vosuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.